FDA approves new buprenorphine injection for opioid use disorder

Buprenorphine extended-release injection (Brixadi) is indicated for the treatment of moderate to severe opioid use disorder. Brixadi is available in two formulations: a weekly SC injection that can be used in patients who've started treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine; and a monthly version for patients already being treated with buprenorphine.